Literature DB >> 22109798

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.

Rekha Lopez1, Julie E Davidson, Matthew D Beeby, Peter J Egger, David A Isenberg.   

Abstract

OBJECTIVES: To estimate the effect of SLE disease activity, observed over a 12-month period, on the risk of irreversible organ damage and mortality, adjusted for potential confounding factors.
METHODS: Patients were enrolled into a prospective cohort study and followed up from 1991. This study retrospectively analyses the data captured in the prospective cohort study. The study population consisted of 350 patients with SLE (meeting four or more of the revised ACR criteria) enrolled at University College Hospital, London lupus clinic. Disease activity was assessed during the observation year using the classic BILAG system and a mean total BILAG score was calculated for that time period. Organ damage outcomes, assessed over a subsequent follow-up period, were based on SLICC/ACR damage index scores and included new damage overall and by specific organ systems (renal, CNS or cardiovascular/musculoskeletal/pulmonary systems) or reaching a serious level of damage (SDI ≥ 3). Adjusted hazard ratios (HRs) for the association between disease activity and subsequent organ damage or mortality were calculated using Cox proportional hazards regression.
RESULTS: Disease activity as measured by mean total BILAG score was associated with mortality (HR = 1.15, P = 0.008), new organ damage (HR = 1.08, P = 0.009) and CV/pulmonary or musculoskeletal damage (HR = 1.11, P = 0.007) after adjustment for age, sex, ethnicity, SLE duration, steroid exposure level, NSAID, anti-malarial or immunosuppressant use, renal activity and complement C3 or anti-dsDNA levels. Of these adjustment factors, age, renal activity, immunosuppressant use and pre-existing organ damage were additional independent predictors.
CONCLUSIONS: Disease activity as measured by global BILAG score during a 12-month observation period predicts the risk of subsequent organ damage and mortality after adjustment for key covariates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109798     DOI: 10.1093/rheumatology/ker368

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  34 in total

1.  Discrimination and Cumulative Disease Damage Among African American Women With Systemic Lupus Erythematosus.

Authors:  David H Chae; Cristina M Drenkard; Tené T Lewis; S Sam Lim
Journal:  Am J Public Health       Date:  2015-08-13       Impact factor: 9.308

2.  Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies.

Authors:  Milena Mimica; Ignacio Barra; Rocío Ormeño; Patricia Flores; Jorge Calderón; Oslando Padilla; Marcela Bravo-Zehnder; Alfonso González; Loreto Massardo
Journal:  Clin Rheumatol       Date:  2019-07-31       Impact factor: 2.980

3.  Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.

Authors:  Tünde Tarr; Gábor Papp; Nikolett Nagy; Edina Cserép; Margit Zeher
Journal:  Clin Rheumatol       Date:  2016-11-26       Impact factor: 2.980

4.  Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Authors:  M Pejchinovski; J Siwy; W Mullen; H Mischak; M A Petri; L C Burkly; R Wei
Journal:  Lupus       Date:  2017-05-05       Impact factor: 2.911

Review 5.  Treatment of severe lupus nephritis: the new horizon.

Authors:  Tak Mao Chan
Journal:  Nat Rev Nephrol       Date:  2014-11-25       Impact factor: 28.314

6.  Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE).

Authors:  E Nasonov; S Soloviev; J E Davidson; A Lila; G Togizbayev; R Ivanova; Ch Baimukhamedov; Zh Omarbekova; O Iaremenko; A Gnylorybov; S Shevchuk; A Vasylyev; M H S Pereira
Journal:  Lupus Sci Med       Date:  2015-02-19

7.  Elicitation of health state utilities associated with varying severities of flares in Systemic Lupus Erythematosus.

Authors:  C Pollard; S Hartz; S Liu Leage; M A Paget; J Cook; A Enstone
Journal:  Health Qual Life Outcomes       Date:  2015-05-28       Impact factor: 3.186

8.  Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.

Authors:  I N Bruce; M Urowitz; R van Vollenhoven; C Aranow; J Fettiplace; M Oldham; B Wilson; C Molta; D Roth; D Gordon
Journal:  Lupus       Date:  2016-03-01       Impact factor: 2.911

Review 9.  The clinical significance of vitamin D in systemic lupus erythematosus: a systematic review.

Authors:  Rajalingham Sakthiswary; Azman Ali Raymond
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 10.  Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?

Authors:  Marilyn C Pike; Lexy Kelley
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.